Pharmaceutical Business review

Sanofi gains rights to Daiichi blood clot treatment

<p>The transfer will be implemented in conformity with local regulatory requirements and the transfer is expected to occur by October 1, 2007.<br /><br />Given their long-standing relationship, both parties agreed to collaborate in the future areas of marketing and distribution in the country. Daiichi is Japan&#0039;s second biggest drugmaker and it promotes Plavix, the best selling blood thinner, with Sanofi in Japan.<br /><br />Plavix won Japanese approval to treat clots in blood vessels that lead to the brain in May 2006.</p>